Filed in archive
Diagnostics, Methodologies and Instrumentation
, Genomics, Proteomics and Bioinformatics
, Other Biotechnology News
by ruth on February 7, 2009

ATryn is indicated for the treatment of patients with hereditary antithrombin deficiency, undergoing high-risk surgical or childbirth procedures. GTC Theapeutics has collaborated with OVATION Pharmaceuticals, Inc. to develop and market ATryn® in the United States.
Tags:
transgenics
atryn
genetics
genetic+engineering
antithrombin
blood+clotting
section
noscript+section
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/142858
Mr Wong
Vote for FDA Approxes ATryn, First Drug from a Genetically Engineered Animal:
|
Rating: 9.00 out of 1 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







